Table 1 Baseline characteristics of the patients

N.

85

29

56

Gender, F/M

62/23

20/9

42/14

Age (years), mean ± SD (median ± IQR)

55.5 ± 12 (56 ± 17)

50.5 ± 14 (52 ± 16)

58 ± 10 (57 ± 15.5)*

Body weight (Kg), mean ± SD (median ± IQR)

75 ± 17 (75 ± 25)

72 ± 14 (72 ± 23)

77 ± 18 (76 ± 26)

Disease duration (years), mean ± SD (median ± IQR)

6.7 ± 1.3 (7 ± 2)

6.6 ± 1.35 (6 ± 3)

6.8 ± 1.2 (7 ± 2)

HLA-B27 carriers, N. (%)

N/A

23 (79)

N/A

Highest disease activity status at baseline, N. (%)

68 (80)

22 (76)

46 (82)

Baseline ASDAS-CRP or DAS28-CRP, mean ± SD (median ± IQR)

-

3.7 ± 0.3 (3.7 ± 0.2)

5.8 ± 0.7 (5.7 ± 0.8)

Concomitant csDMARDs, N. (%)

61 (72)

7 (24)

54 (96)****

Concomitant MTX, N. (%)

58 (68)

7 (24)

51 (91)****

Concomitant NSAIDs, N. (%)

N/A

26 (90)

N/A

TNFi-experienced, N. (%)

13 (15)

4 (14)

9 (16)